NASDAQ:INZY Inozyme Pharma (INZY) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free INZY Stock Alerts $4.44 +0.11 (+2.54%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$4.23▼$4.5150-Day Range$4.33▼$7.6652-Week Range$2.69▼$7.80Volume511,357 shsAverage Volume821,554 shsMarket Capitalization$274.26 millionP/E RatioN/ADividend YieldN/APrice Target$17.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Inozyme Pharma alerts: Email Address Inozyme Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside282.9% Upside$17.00 Price TargetShort InterestBearish7.66% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$52,210 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.46) to ($1.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.24 out of 5 starsMedical Sector750th out of 913 stocksPharmaceutical Preparations Industry345th out of 423 stocks 3.5 Analyst's Opinion Consensus RatingInozyme Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInozyme Pharma has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.66% of the float of Inozyme Pharma has been sold short.Short Interest Ratio / Days to CoverInozyme Pharma has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Inozyme Pharma has recently increased by 22.09%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInozyme Pharma does not currently pay a dividend.Dividend GrowthInozyme Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INZY. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 4 people have searched for INZY on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows4 people have added Inozyme Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inozyme Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $52,210.00 in company stock.Percentage Held by Insiders11.88% of the stock of Inozyme Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.30% of the stock of Inozyme Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Inozyme Pharma are expected to decrease in the coming year, from ($1.46) to ($1.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inozyme Pharma is -3.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inozyme Pharma is -3.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInozyme Pharma has a P/B Ratio of 1.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About Inozyme Pharma Stock (NASDAQ:INZY)Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Read More INZY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INZY Stock News HeadlinesApril 4, 2024 | insidertrades.comInozyme Pharma, Inc. (NASDAQ:INZY) CEO Douglas A. Treco Sells 7,523 SharesApril 9, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Inozyme Pharma (INZY), Moderna (MRNA)April 27, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.April 8, 2024 | markets.businessinsider.comInozyme Reports Positive Topline Data From Phase 1/2 Study Of INZ-701; Stock UpApril 8, 2024 | globenewswire.comInozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 DeficiencyApril 5, 2024 | globenewswire.comInozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2024 | globenewswire.comInozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 26, 2024 | globenewswire.comInozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024April 27, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.March 13, 2024 | markets.businessinsider.comBuy Rating for Inozyme Pharma Backed by Promising Clinical Progress and Unique Market Positioning of INZ-701March 12, 2024 | benzinga.comInozyme Pharma: Q4 Earnings InsightsMarch 12, 2024 | benzinga.comInozyme Pharma: Q4 Earnings InsightsMarch 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Inozyme Pharma as Phase I/II Trial Updates and Strong Cash Position Bolster ConfidenceMarch 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Inozyme Pharma as Phase I/II Trial Updates and Strong Cash Position Bolster ConfidenceMarch 12, 2024 | markets.businessinsider.comInozyme Pharma: Strong Buy Rating Amidst Promising Trial Developments and Market UnderappreciationMarch 12, 2024 | finanznachrichten.deInozyme Pharma Inc.: Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business HighlightsMarch 12, 2024 | globenewswire.comInozyme Pharma Reports Full Year 2023 Financial Results and Provides Business HighlightsFebruary 26, 2024 | globenewswire.comInozyme Pharma to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 25, 2024 | finance.yahoo.comINZY May 2024 5.000 putFebruary 24, 2024 | benzinga.comInozyme Pharma Stock (NASDAQ:INZY), Short Interest ReportFebruary 22, 2024 | benzinga.comBakker Juliet Tammenoms's Net WorthJanuary 30, 2024 | finance.yahoo.comInozyme Pharma, Inc. (INZY)January 19, 2024 | morningstar.comInozyme Pharma Inc Ordinary Shares INZYDecember 21, 2023 | finance.yahoo.comInstitutional investors own a significant stake of 45% in Inozyme Pharma, Inc. (NASDAQ:INZY)November 9, 2023 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Inozyme Pharma (INZY)November 7, 2023 | finance.yahoo.comInozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business HighlightsOctober 26, 2023 | finance.yahoo.comInozyme Pharma Announces Presentation at the American Society of Nephrology (ASN) Kidney Week 2023See More Headlines Receive INZY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today4/27/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:INZY CUSIPN/A CIK1693011 Webwww.inozyme.com Phone857-330-4340FaxN/AEmployees59Year FoundedN/APrice Target and Rating Average Stock Price Target$17.00 High Stock Price Target$23.00 Low Stock Price Target$14.00 Potential Upside/Downside+282.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,170,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-55.86% Return on Assets-40.71% Debt Debt-to-Equity Ratio0.32 Current Ratio13.36 Quick Ratio13.36 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.27 per share Price / Book1.96Miscellaneous Outstanding Shares61,770,000Free Float54,433,000Market Cap$274.26 million OptionableOptionable Beta1.37 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Douglas A. Treco Ph.D. (Age 66)CEO & Chairman Comp: $77kMr. Axel Bolte M.B.A. (Age 52)M.Sc., Co-Founder, Senior Advisor & Director Comp: $1.03MMr. Sanjay S. Subramanian M.B.A. (Age 47)M.S., Senior VP, CFO & Principal Accounting Officer Comp: $726.3kDr. Demetrios Braddock M.D.Ph.D., Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board ObserverDr. Matthew Winton Ph.D. (Age 46)Senior VP & COO Dr. Soojin Kim Ph.D.Senior VP & Chief Technical Operations OfficerDr. David Thompson M.A.M.S., Ph.D., Senior VP, Chief Scientific Officer & Chief Development OfficerMr. Stefan RileyDirector of Investor RelationsMs. Gayle GirondaSenior VP & Chief People OfficerDr. Yves Sabbagh Ph.D.Chairman of Scientific Advisory Board & Senior VPMore ExecutivesKey CompetitorsNanobiotixNASDAQ:NBTXVanda PharmaceuticalsNASDAQ:VNDAEnanta PharmaceuticalsNASDAQ:ENTARAPT TherapeuticsNASDAQ:RAPTWerewolf TherapeuticsNASDAQ:HOWLView All CompetitorsInsiders & InstitutionsDouglas A TrecoSold 7,523 sharesTotal: $52,209.62 ($6.94/share)Eventide Asset Management LLCBought 54,837 shares on 2/20/2024Ownership: 5.149%Octagon Capital Advisors LPSold 900,000 shares on 2/15/2024Ownership: 0.648%Superstring Capital Management LPBought 123,944 shares on 2/14/2024Ownership: 0.201%Affinity Asset Advisors LLCBought 505,950 shares on 2/13/2024Ownership: 3.053%View All Insider TransactionsView All Institutional Transactions INZY Stock Analysis - Frequently Asked Questions Should I buy or sell Inozyme Pharma stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inozyme Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INZY shares. View INZY analyst ratings or view top-rated stocks. What is Inozyme Pharma's stock price target for 2024? 4 brokerages have issued 1-year price targets for Inozyme Pharma's shares. Their INZY share price targets range from $14.00 to $23.00. On average, they predict the company's share price to reach $17.00 in the next twelve months. This suggests a possible upside of 282.9% from the stock's current price. View analysts price targets for INZY or view top-rated stocks among Wall Street analysts. How have INZY shares performed in 2024? Inozyme Pharma's stock was trading at $4.26 at the beginning of 2024. Since then, INZY stock has increased by 4.2% and is now trading at $4.44. View the best growth stocks for 2024 here. Are investors shorting Inozyme Pharma? Inozyme Pharma saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 2,580,000 shares, an increase of 8.4% from the March 15th total of 2,380,000 shares. Based on an average daily volume of 611,300 shares, the short-interest ratio is presently 4.2 days. Currently, 6.3% of the company's stock are short sold. View Inozyme Pharma's Short Interest. When is Inozyme Pharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our INZY earnings forecast. How were Inozyme Pharma's earnings last quarter? Inozyme Pharma, Inc. (NASDAQ:INZY) announced its quarterly earnings data on Tuesday, March, 12th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $0.04. What other stocks do shareholders of Inozyme Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Inozyme Pharma investors own include Procter & Gamble (PG), RTX (RTX), Cisco Systems (CSCO), CSX (CSX), CVS Health (CVS), Home Depot (HD), Resideo Technologies (REZI), Thermo Fisher Scientific (TMO) and Abbott Laboratories (ABT). When did Inozyme Pharma IPO? Inozyme Pharma (INZY) raised $75 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager. How do I buy shares of Inozyme Pharma? Shares of INZY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INZY) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithProtect Your Bank Account Before It’s Too LateWeiss RatingsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inozyme Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
